<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from Circa
Pharmaceuticals, Inc. consolidated financial statements for the fiscal year
ended December 31, 1994 and is qualified in its entirety by reference to such
financial statements.
</LEGEND>
<CIK> 0000013006
<NAME> CIRCA PHARMACEUTICALS, INC.
       
                             
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1994
<PERIOD-END>                               DEC-31-1994
<CASH>                                        19666933
<SECURITIES>                                  30533630
<RECEIVABLES>                                  4034728
<ALLOWANCES>                                    405000
<INVENTORY>                                    1697710
<CURRENT-ASSETS>                              57656175
<PP&E>                                        30132203
<DEPRECIATION>                                17644083
<TOTAL-ASSETS>                               103857032
<CURRENT-LIABILITIES>                          6218615
<BONDS>                                              0
<COMMON>                                        221101
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<OTHER-SE>                                    81780242
<TOTAL-LIABILITY-AND-EQUITY>                 103857032
<SALES>                                        6592393
<TOTAL-REVENUES>                               7801481
<CGS>                                          3629297
<TOTAL-COSTS>                                  3629297
<OTHER-EXPENSES>                              19499097
<LOSS-PROVISION>                                209074
<INTEREST-EXPENSE>                              591448
<INCOME-PRETAX>                               17369045
<INCOME-TAX>                                    110000
<INCOME-CONTINUING>                           17259045
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  17259045
<EPS-PRIMARY>                                      .79
<EPS-DILUTED>                                      .79